Malignant Neuroleptic Syndrome following Deep Brain Stimulation Surgery of Globus Pallidus Pars Internus in Cerebral Palsy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Neuroleptic malignant syndrome (NMS) is a rare but potentially lethal outcome caused by sudden discontinuation or dose reduction of dopaminergic agents. We report an extremely rare case of NMS after deep brain stimulation (DBS) surgery in a cerebral palsy (CP) patient without the withdrawal of dopaminergic agents. A 19-year-old girl with CP was admitted for DBS due to medically refractory dystonia and rigidity. Dopaminergic agents were not stopped preoperatively. DBS was performed uneventfully under monitored anesthesia. Dopaminergic medication was continued during the postoperative period. She manifested spasticity and muscle rigidity, and was high fever resistant to anti-pyretic drugs at 2 h postoperative. At postoperative 20 h, she suffered cardiac arrest and expired, despite vigorous cardiopulmonary resuscitation. NMS should be considered for hyperthermia and severe spasticity in CP patients after DBS surgery, irrespective of continued dopaminergic medication.
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but potentially lethal outcome caused by sudden discontinuation or dose reduction of dopaminergic agents. We report an extremely rare case of NMS after deep brain stimulation (DBS) surgery in a cerebral palsy (CP) patient without the withdrawal of dopaminergic agents. A 19-year-old girl with CP was admitted for DBS due to medically refractory dystonia and rigidity. Dopaminergic agents were not stopped preoperatively. DBS was performed uneventfully under monitored anesthesia. Dopaminergic medication was continued during the postoperative period. She manifested spasticity and muscle rigidity, and was high fever resistant to anti-pyretic drugs at 2 h postoperative. At postoperative 20 h, she suffered cardiac arrest and expired, despite vigorous cardiopulmonary resuscitation. NMS should be considered for hyperthermia and severe spasticity in CP patients after DBS surgery, irrespective of continued dopaminergic medication.
참고문헌 (19)
- Vidailhet M, "Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study", Lancet Neurol, 8, pp.709~717 (2009)
- Jankovic J, "Dystonia: medical therapy and botulinum toxin", Adv Neurol, 94, pp.275~286 (2004)
- Bhidayasiri R, "Dystonia: genetics and treatment update", Neurologist, 12, pp.74~85 (2006)
- Ae Ryoung Kim, "Two-Year Outcomes of Deep Brain Stimulation in Adults With Cerebral Palsy", Annals of Rehabilitation Medicine, 38(2), pp.209~217 (2014), 대한재활의학회
- Adnet P, "Neuroleptic malignant syndrome", Br J Anaesth, 85, pp.129~135 (2000)
- Newman EJ, "The parkinsonism-hyperpyrexia syndrome", Neurocrit Care, 10, pp.136~140 (2009)
- Kipps CM, "Movement disorder emergencies", Mov Disord, 20, pp.322~334 (2005)
- Nicholson D, "Neuroleptic malignant syndrome", Geriatrics, 59, pp.36~ (2004)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-IV-TR", American Psychiatric Association, 795~798 (2000)
- Levenson JL, "Neuroleptic malignant syndrome", Am J Psychiatry, 142, pp.1137~1145 (1985)
- Pranzatelli MR, "Oral pharmacotherapy for the movement disorders of cerebral palsy", J Child Neurol, 11(1), pp.S13~S22 (1996)
- DeLong M, "Deep brain stimulation for movement and other neurologic disorders", Ann N Y Acad Sci, 1265, pp.1~8 (2012)
- Benabid AL, "Long-term electrical inhibition of deep brain targets in movement disorders", Mov Disord, 13(3), pp.119~125 (1998)
- Vercueil L, "Results of deep brain stimulation for dystonia: a critical reappraisal", Mov Disord, 17(3), pp.S89~S93 (2002)
- Counelis GJ, "Bilateral subthalamic nucleus deep brain stimulation for advanced PD: correlation of intraoperative MER and postoperative MRI with neuropathological findings", Mov Disord, 18, pp.1062~1065 (2003)
- Urasaki E, "Neuroleptic malignant syndrome (parkinsonism-hyperpyrexia syndrome) after deep brain stimulation of the subthalamic nucleus", J Clin Neurosci, 20, pp.740~741 (2013)
- Perry D, "Neuroleptic malignant syndrome associated with the use of carbidopa", levodopa for dystonia in persons with cerebral palsy, 2012, pp.4, 383~384
- Sakkas P, "Drug treatment of the neuroleptic malignant syndrome", Psychopharmacol Bull, 27, pp.381~384 (1991)
- Tse L, "Neuroleptic malignant syndrome: a review from a clinically oriented perspective", Curr Neuropharmacol, 13, pp.395~406 (2015)